Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team with proven ability to develop therapies for CNS ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

In a release issued under the same headline earlier today by HPQ Silicon Inc. , please note that in the 11th paragraph, the number of units issued is not 1,009,343 but 1,083,333. The revised release ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

Dr. McClure's distinguished track record in designing and directing successful early-to-late-stage clinical trials, which include several marketed products, further demonstrates Lifordi's commitment ...

Cytrellis Biosystems, Inc., a pioneer in novel medical aesthetic solutions, today announced the launch of the updated ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.